StimLabs was founded in 2015 with a desire to advance the state of regenerative medicine. In pursuit of this goal, StimLabs has gathered exceptional scientific and clinical minds to develop and commercialize new bioactive technologies. Within a year of its inception, StimLabs conceptualized and launched a suite of amniotic-derived products, developed an extensive product pipeline across a range of clinical applications, and established a portfolio of intellectual property.
Amniotic Tissue β’ Regenerative Medicine β’ Allograft Tissue
201 - 500 employees
Founded 2015